Abstract
This chapter reviews important considerations for the performance and interpretation of [18F]fluorodeoxyglucose (FDG)-PET/CT in the diagnostic evaluation of patients with esophageal cancer. Accurate staging is the primary basis for selecting appropriate treatment for patients with esophageal cancer. Attention to patient preparation, imaging protocols, potential artifacts and diagnostic pitfalls are critical for performing high quality FDG-PET/CT studies. The most established role of FDG-PET/CT in esophageal cancer is for staging of disease, particularly for the detection of distant metastatic disease. There is also evidence that FDG-PET/CT can be used to evaluate response to neoadjuvant therapy, although the impact on patient outcomes is not yet well-established.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Adams MC, Turkington TG, Wilson JM, et al. A systematic review of the factors affecting accuracy of SUV measurements. AJR Am J Roentgenol. 2010;195:310–20.
Berghmans T, Dusart M, Paesmans M, et al. Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis (MA) by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project. J Thorac Oncol. 2008;3:6–12.
Beyer T, Antoch G, Muller S, et al. Acquisition protocol considerations for combined PET/CT imaging. J Nucl Med. 2004;45(Suppl 1):25S–35.
Bockisch A, Beyer T, Antoch G, et al. Positron emission tomography/computed tomography–imaging protocols, artifacts, and pitfalls. Mol Imaging Biol. 2004;6:188–99.
Bundschuh RA, Martinez-Moeller A, Essler M, et al. Postacquisition detection of tumor motion in the lung and upper abdomen using list-mode PET data: a feasibility study. J Nucl Med. 2007;48:758–63.
Cheze-Le Rest C, Metges JP, Teyton P, et al. Prognostic value of initial fluorodeoxyglucose-PET in esophageal cancer: a prospective study. Nucl Med Commun. 2008;29:628–35.
Dehdashti F, Siegel BA. Neoplasms of the esophagus and stomach. Semin Nucl Med. 2004;34:198–208.
Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med. 2003;349:2241–52.
Even-Sapir E, Lerman H, Gutman M, et al. The presentation of malignant tumours and pre-malignant lesions incidentally found on PET-CT. Eur J Nucl Med Mol Imaging. 2006;33:541–52.
Gallagher BM, Fowler JS, Gutterson NI, et al. Metabolic trapping as a principle of oradiopharmaceutical design: some factors responsible for the biodistribution of [18F] 2-deoxy-2-fluoro-D-glucose. J Nucl Med. 1978;19:1154–61.
Guo H, Zhu H, Xi Y, et al. Diagnostic and prognostic value of 18F-FDG PET/CT for patients with suspected recurrence from squamous cell carcinoma of the esophagus. J Nucl Med. 2007;48:1251–8.
Hatt M, Visvikis D, Albarghach NM, et al. Prognostic value of (18)F-FDG PET image-based parameters in oesophageal cancer and impact of tumour delineation methodology. Eur J Nucl Med Mol Imaging. 2011;38(7):1191–202.
Hicks RJ, Binns D, Stabin MG. Pattern of uptake and excretion of (18)F-FDG in the lactating breast. J Nucl Med. 2001;42:1238–42.
Hiyoshi Y, Watanabe M, Imamura Y, et al. The relationship between the glucose transporter type 1 expression and F-fluorodeoxyglucose uptake in esophageal squamous cell carcinoma. Oncology. 2009;76:286–92.
ICRP. Radiation dose to patients from radiopharmaceuticals. Addendum 3 to ICRP Publication 53. ICRP Publication 106. Approved by the Commission in October 2007. Ann ICRP. 2008;38:1–197.
Jacene HA, Ishimori T, Engles JM, et al. Effects of pegfilgrastim on normal biodistribution of 18F-FDG: preclinical and clinical studies. J Nucl Med. 2006;47:950–6.
Kato H, Kimura H, Nakajima M, et al. The additional value of integrated PET/CT over PET in initial lymph node staging of esophageal cancer. Oncol Rep. 2008;20:857–62.
Kato H, Nakajima M, Sohda M, et al. The clinical application of (18)F-fluorodeoxyglucose positron emission tomography to predict survival in patients with operable esophageal cancer. Cancer. 2009;115:3196–203.
Keswani RN, Early DS, Edmundowicz SA, et al. Routine positron emission tomography does not alter nodal staging in patients undergoing EUS-guided FNA for esophageal cancer. Gastrointest Endosc. 2009;69:1210–17.
Kidd EA, Siegel BA, Dehdashti F, et al. The standardized uptake value for F-18 fluorodeoxyglucose is a sensitive predictive biomarker for cervical cancer treatment response and survival. Cancer. 2007;110:1738–44.
Kim SK, Kang KW, Roh JW, et al. Incidental ovarian 18F-FDG accumulation on PET: correlation with the menstrual cycle. Eur J Nucl Med Mol Imaging. 2005;32:757–63.
Krause BJ, Herrmann K, Wieder H, et al. 18F-FDG PET and 18F-FDG PET/CT for assessing response to therapy in esophageal cancer. J Nucl Med. 2009;50(Suppl 1):89S–96.
Krishnasetty V, Bonab AA, Fischman AJ, et al. Comparison of standard-dose vs low-dose attenuation correction CT on image quality and positron emission tomographic attenuation correction. J Am Coll Radiol. 2008;5:579–84.
Lin E. F-18 fluorodeoxyglucose uptake in a benign gastric ulcer. Clin Nucl Med. 2007;32:462–3.
Lin CY, Ding HJ, Liu CS, et al. Correlation between the intensity of breast FDG uptake and menstrual cycle. Acad Radiol. 2007;14:940–4.
Lucignani G, Larson SM. Doctor, what does my future hold? The prognostic value of FDG-PET in solid tumours. Eur J Nucl Med Mol Imaging. 2010;37:1032–8.
Matsuki A, Kosugi S, Kanda T, et al. Schwannoma of the esophagus: a case exhibiting high 18F-fluorodeoxyglucose uptake in positron emission tomography imaging. Dis Esophagus. 2009;22:E6–10.
Metser U, Miller E, Lerman H, et al. Benign nonphysiologic lesions with increased 18F-FDG uptake on PET/CT: characterization and incidence. AJR Am J Roentgenol. 2007;189:1203–10.
Meyers BF, Downey RJ, Decker PA, et al. The utility of positron emission tomography in staging of potentially operable carcinoma of the thoracic esophagus: results of the American College of Surgeons Oncology Group Z0060 trial. J Thorac Cardiovasc Surg. 2007;133:738–45.
Mochizuki T, Tsukamoto E, Kuge Y, et al. FDG uptake and glucose transporter subtype expressions in experimental tumor and inflammation models. J Nucl Med. 2001;42:1551–5.
Ng SH, Chan SC, Liao CT, et al. Distant metastases and synchronous second primary tumors in patients with newly diagnosed oropharyngeal and hypopharyngeal carcinomas: evaluation of (18)F-FDG PET and extended-field multi-detector row CT. Neuroradiology. 2008;50:969–79.
Ouellet V, Routhier-Labadie A, Bellemare W, et al. Outdoor temperature, age, sex, body mass index, and diabetic status determine the prevalence, mass, and glucose-uptake activity of 18F-FDG-detected BAT in humans. J Clin Endocrinol Metab. 2011;96:192–9.
Pace L, Nicolai E, D’Amico D, et al. Determinants of physiologic (18)F-FDG uptake in brown adipose tissue in sequential PET/CT examinations. Mol Imaging Biol 2011;13:1029–35.
Pan L, Gu P, Huang G, et al. Prognostic significance of SUV on PET/CT in patients with esophageal cancer: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2009;21:1008–15.
Parysow O, Mollerach AM, Jager V, et al. Low-dose oral propranolol could reduce brown adipose tissue F-18 FDG uptake in patients undergoing PET scans. Clin Nucl Med. 2007;32:351–7.
Pauwels EK, Ribeiro MJ, Stoot JH, et al. FDG accumulation and tumor biology. Nucl Med Biol. 1998;25:317–22.
Quon A, Fischbein NJ, McDougall IR, et al. Clinical role of 18 F-FDG PET/CT in the management of squamous cell carcinoma of the head and neck and thyroid carcinoma. J Nucl Med. 2007;48(Suppl 1):58S–67.
Rice TW, Blackstone EH, Rusch VW. 7th edition of the AJCC cancer staging manual: esophagus and esophagogastric junction. Ann Surg Oncol. 2010;17:1721–4.
Rizk NP, Tang L, Adusumilli PS, et al. Predictive value of initial PET-SUVmax in patients with locally advanced esophageal and gastroesophageal junction adenocarcinoma. J Thorac Oncol. 2009;4:875–9.
Roedl JB, Colen RR, King K, et al. Visual PET/CT scoring for nonspecific 18F-FDG uptake in the differentiation of early malignant and benign esophageal lesions. AJR Am J Roentgenol. 2008;191:515–21.
Roy FN, Beaulieu S, Boucher L, et al. Impact of intravenous insulin on 18 F-FDG PET in diabetic cancer patients. J Nucl Med. 2009;50:178–83.
Shenfine J, Barbour AP, Wong D, et al. Prognostic value of maximum standardized uptake values from preoperative positron emission tomography in resectable adenocarcinoma of the esophagus treated by surgery alone. Dis Esophagus. 2009;22:668–75.
Shyn PB. Protocol considerations for thoracic positron emission tomography-computed tomography. Semin Ultrasound CT MR. 2008;29:242–50.
Soderlund V, Larsson SA, Jacobsson H. Reduction of FDG uptake in brown adipose tissue in clinical patients by a single dose of propranolol. Eur J Nucl Med Mol Imaging. 2007;34:1018–22.
Thomas Jr CR. Biology of esophageal cancer and the role of combined modality therapy. Surg Clin North Am. 1997;77:1139–67.
Uldry M, Thorens B. The SLC2 family of facilitated hexose and polyol transporters. Pflugers Arch. 2004;447:480–9.
van Westreenen HL, Westerterp M, Bossuyt PM, et al. Systematic review of the staging performance of 18F-fluorodeoxyglucose positron emission tomography in esophageal cancer. J Clin Oncol. 2004;22:3805–12.
van Westreenen HL, Plukker JT, Cobben DC, et al. Prognostic value of the standardized uptake value in esophageal cancer. AJR Am J Roentgenol. 2005;185:436–40.
Wahl RL, Jacene H, Kasamon Y, et al. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50(Suppl 1):122S–50.
Werner MK, Parker JA, Kolodny GM, et al. Respiratory gating enhances imaging of pulmonary nodules and measurement of tracer uptake in FDG PET/CT. AJR Am J Roentgenol. 2009;193:1640–5.
Wieder HA, Krause BJ, Herrmann K. PET and PET-CT in esophageal and gastric cancer. Methods Mol Biol. 2011;727:59–76.
Yuan S, Yu Y, Chao KS, et al. Additional value of PET/CT over PET in assessment of locoregional lymph nodes in thoracic esophageal squamous cell cancer. J Nucl Med. 2006;47:1255–9.
Zhuang H, Pourdehnad M, Lambright ES, et al. Dual time point 18 F-FDG PET imaging for differentiating malignant from inflammatory processes. J Nucl Med. 2001;42:1412–17.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer-Verlag Berlin Heidelberg
About this entry
Cite this entry
McConathy, J.E., Dehdashti, F. (2013). Pharynx and Esophagus: PET/CT. In: Hamm, B., Ros, P.R. (eds) Abdominal Imaging. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-13327-5_195
Download citation
DOI: https://doi.org/10.1007/978-3-642-13327-5_195
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-13326-8
Online ISBN: 978-3-642-13327-5
eBook Packages: MedicineReference Module Medicine